



Press Release

Granules India's Revenue increases 19% to Rs. 366 Cr.; Net Profit surges 40% to Rs. 31 Cr.

Hyderabad, October 31, 2015: Granules India Ltd., a fast growing pharmaceutical manufacturing company, announced financial results for its second quarter ended 30th September, 2015.

Consolidated Q2FY16 Financial Results Highlights:-

- **Revenue:** Rs. 366 Cr., an increase of 19% compared to Rs. 308 Cr. in Q2FY15
- **EBITDA:** Rs. 70 Cr., an increase of 33% compared to Rs. 53 Cr. in Q2FY15
- **Operating Margin** improved by 204 basis point to 19.2% from 17.2% in Q2FY15
- **Net Profit:** Rs. 31 Cr., an increase of 40% compared to Rs. 22 Cr. in Q2FY15
- **Net Profit Margin** improved by 128 basis point to 8.5% from 7.2% in Q2FY15

Break-up of Q2FY16 Consolidated Sales:-

- **Vertical wise:-**
 - Active Pharmaceutical Ingredients (APIs): 44%
 - Pharmaceutical Formulation Intermediaries (PFIs): 27%
 - Finished Dosages (FDs): 29%
- **Geography wise:-**
 - Regulated Markets: 55%
 - Rest of the World Markets (ROW): 45%

The Company's standalone sales during the quarter were Rs. 333 Cr., an increase of 22% from the same quarter previous year. EBITDA and PAT are recorded at Rs. 64 Cr. and Rs. 27 Cr. in this quarter, an increase by 14% and 3% from Q2FY15.

The Board of Directors has approved payment of second interim dividend of 15 paise per share of face value of Rs. 1 each for the financial year 2015-16.

“Our continuous endeavour to improve operational efficiency and process innovation has resulted yet another strong quarter for us. We are happy to see growth in Revenue and Profit along with improved margin profiles compared to the same quarter previous year. We remain focused on strengthening our core businesses, developing a differentiated product basket through new API division and increasing our global footprints by capitalising the strategic efforts.” said Mr. C Krishna Prasad, Chairman & Managing Director of Granules India.



About Granules India Ltd.

(BSE: 532482, NSE: GRANULES)

Granules is a fast growing pharmaceutical manufacturing company with world class facilities and is committed to manufacturing excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets. Granules support customers with unique value, extensive product range, proactive solutions and a global network of associates. The Company's global presence extends to over 300 customers in 60 countries through offices in India, U.S., U.K., China and Colombia. Granules offer all three components of the pharmaceutical value chain which gives the customers flexibility and choice.

The Company has its own ANDAs and dossiers which enable customers to quickly enter a market instead of filing their own applications. Granules has a highly skilled regulatory affairs department that can offer customers support and can help them navigate through regulatory issues.

Caution Statement:

Certain statements made above may be "forward looking statements" within the meaning of applicable laws and regulations.

Contacts:

Sumanta Bajpayee
Granules India Ltd.
040-30663572
sumanta.bajpayee@granulesindia.com

Govindan JM
Genesis Burson-Marsteller
+91 9703700884
Govindan.JM@bm.com